← Back to Analyst Consensus 
MCRB Buy
Seres Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 3, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Mar 13, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 24, 2025 | Canaccord Genuity | maintain | Buy → Buy | $22 | 48% |
| May 8, 2025 | Chardan Capital | downgrade | Buy → Neutral | $6 | 46% |
| Mar 20, 2025 | Chardan Capital | maintain | Buy → Buy | $1.25 | 46% |
| Mar 14, 2025 | Goldman Sachs | maintain | Sell → Sell | $0.75 | 54% |
| Nov 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $10 | 48% |
| Nov 13, 2024 | Chardan Capital | maintain | Buy → Buy | $1.25 | 46% |
| Oct 24, 2024 | JP Morgan | downgrade | Neutral → Underweight | $0 | 54% |
| Sep 13, 2024 | Canaccord Genuity | maintain | Buy → Buy | $10 | 48% |
| Aug 14, 2024 | Canaccord Genuity | maintain | Buy → Buy | $10 | 48% |
| Aug 14, 2024 | Chardan Capital | maintain | Buy → Buy | $1.25 | 46% |
| Jun 7, 2024 | Oppenheimer | downgrade | Outperform → Perform | $0 | 52% |
| Jun 7, 2024 | Canaccord Genuity | maintain | Buy → Buy | $10 | 48% |
| May 9, 2024 | Oppenheimer | maintain | Outperform → Outperform | $4 | 52% |
| May 8, 2024 | Chardan Capital | maintain | Buy → Buy | $6 | 46% |
| Mar 6, 2024 | Oppenheimer | maintain | Outperform → Outperform | $5 | 52% |
| Mar 6, 2024 | Chardan Capital | maintain | Buy → Buy | $8 | 46% |
| Jan 16, 2024 | Oppenheimer | maintain | Outperform → Outperform | $9 | 52% |
| Nov 3, 2023 | Goldman Sachs | maintain | Sell → Sell | $1.25 | 54% |
| Apr 28, 2023 | Chardan Capital | maintain | — → Buy | $10 | 46% |
| Apr 21, 2023 | JP Morgan | initiate | — → Neutral | $7 | 54% |
| Mar 21, 2023 | Canaccord Genuity | maintain | — → Buy | $15 | 48% |
| Mar 8, 2023 | Canaccord Genuity | maintain | — → Buy | $11 | 48% |
| Mar 8, 2023 | Chardan Capital | reiterate | — → Buy | $12 | 46% |
| Mar 8, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $25 | 44% |
| Feb 8, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $25 | 44% |
| Sep 7, 2022 | Piper Sandler | maintain | — → Overweight | $9 | 54% |
| May 23, 2022 | Piper Sandler | maintain | — → Overweight | $7 | 54% |
| Jul 23, 2021 | Canaccord Genuity | maintain | — → Buy | $29 | 48% |
| Jul 23, 2021 | Chardan Capital | maintain | — → Buy | $16 | 46% |
| Jul 23, 2021 | Oppenheimer | maintain | — → Outperform | $18 | 52% |
| Jul 23, 2021 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Jul 23, 2021 | Goldman Sachs | downgrade | Neutral → Sell | $7 | 54% |
| May 5, 2021 | HC Wainwright & Co. | maintain | — → Buy | $46 | 44% |
| Mar 5, 2021 | Chardan Capital | upgrade | Neutral → Buy | $30 | 46% |
| Dec 23, 2020 | JMP Securities | initiate | — → Market Perform | $0 | 53% |
| Sep 21, 2020 | Canaccord Genuity | maintain | — → Buy | $42 | 48% |
| Sep 18, 2020 | Chardan Capital | downgrade | Buy → Neutral | $27.5 | 46% |
| Aug 18, 2020 | Piper Sandler | initiate | — → Overweight | $40 | 54% |
| Aug 11, 2020 | HC Wainwright & Co. | maintain | — → Buy | $41 | 44% |
| Aug 11, 2020 | Jefferies | upgrade | Hold → Buy | $29 | 52% |
| Aug 11, 2020 | Chardan Capital | maintain | — → Buy | $32.5 | 46% |
| Mar 31, 2020 | Oppenheimer | maintain | — → Outperform | $7 | 52% |
| Apr 30, 2019 | Jefferies | initiate | — → Hold | $7 | 52% |
| Oct 22, 2018 | Chardan Capital | initiate | — → Buy | $15 | 46% |
| Aug 3, 2018 | B of A Securities | downgrade | Neutral → Underperform | $0 | 53% |
| Oct 13, 2017 | Oppenheimer | initiate | — → Outperform | $19 | 52% |
| Oct 6, 2017 | Seaport Global | initiate | — → Buy | $20 | 51% |
| Dec 16, 2016 | Cantor Fitzgerald | initiate | — → Overweight | $16 | 50% |
Price Target Trend
May 12, 2026 Oct 27, 2026
EPS Estimates
+1y —
0q —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days